The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

January 17, 2020

Study Completion Date

January 21, 2020

Conditions

Chronic Hepatitis C

Interventions

DRUG

HEC74647PA capsule

Capsule administered orally once daily

DRUG

placebo

HEC74647PA capsule matching placebo administered orally once daily

Trial Locations (1)

The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04201275 - The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects | Biotech Hunter | Biotech Hunter